Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Jorge E. Cortes, MD, Stuart L. Goldberg, MD, Mauricette Michallet, MD PhD, Rüdiger Hehlmann, MD, Bengt Simonsson, MD, Michael J. Mauro, MD, Loretta A. Williams, PhD MSN, BSN, BA, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Ginny P Sen, MPH, Aimee Foreman, MA, Srikanth Gajavelli, MD, Carlo Gambacorti-Passerini, MD

Blood (2017) 130 (Supplement 1): 2894.

https://doi.org/10.1182/blood.V130.Suppl_1.2894.2894

Published: 2017

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Stuart Goldberg, MD, Mauricette Michallet, MD PhD, Rudiger Hehlmann, MD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Aimee Foreman, Brian Calimlim, Ron Paquette, MD, Bengt Simonsson, MD, Carlo Gambacorti, MD PhD, Jorge E. Cortes, MD, Aleksandra Zagorska, Yuanxin Rong, Michael J. Mauro, MD

Blood (2016) 128 (22): 937.

https://doi.org/10.1182/blood.V128.22.937.937

Published: 2016

Journal Articles

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Blood (2015) 126 (23): 2780.

https://doi.org/10.1182/blood.V126.23.2780.2780

Published: 2015

Journal Articles

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Markus Pfirrmann, Joerg Hasford, MD, Susanne Saussele, Anna Turkina, Prof., MD, Witold Prejzner, MD, Juan Luis Steegmann, MD, Bengt Simonsson, MD, Andrey Zaritskey, MD, Adriana Colita, MD, Daniela Zackova, MD, Jeroen Janssen, MD, Francisco Cervantes, Karel Indrak, MD, Joelle Guilhot, PhD, Ruediger Hehlmann, MD, Michele Baccarani, MD

Blood (2015) 126 (23): 595.

https://doi.org/10.1182/blood.V126.23.595.595

Published: 2015

Journal Articles

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Blood (2014) 124 (21): 3145.

https://doi.org/10.1182/blood.V124.21.3145.3145

Published: 2014

Journal Articles

Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)

Michael Mauro, MD, Carlo Gambacorti-Passerini, Stuart L Goldberg, Jorge E. Cortes, H. Jean Khoury, MD, Mauricette Michallet, MD PhD, Ronald Paquette, MD, Bengt Simonsson, MD PhD, Michelle P Turner, MS in Biostatistics, Hesham Mohamed, MD, Milayna Subar, MD, Teresa Zyczynski, Pharm.D., MPH

Blood (2014) 124 (21): 3151.

https://doi.org/10.1182/blood.V124.21.3151.3151

Published: 2014

Journal Articles

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Blood (2014) 124 (21): 3160.

https://doi.org/10.1182/blood.V124.21.3160.3160

Published: 2014

Journal Articles

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Richard A. Larson, Rena Conti, PhD, William V. Padula, PhD, Jane F. Apperley, Michele Baccarani, MD, Ekkehard Eigendorff, MD, Francois Guilhot, MD, Joelle Guilhot, PhD, Francois-Xavier Mahon, MD PhD, Giovanni Martinelli, MD, Jiri Mayer, Prof., MD PhD, Martin C. Mueller, Dietger Niederwieser, MD, Susanne Saussele, MD, Charles A. Schiffer, MD, Richard T. Silver, MD, Bengt Simonsson, MD PhD, Rudiger Hehlmann, MD

Blood (2014) 124 (21): 738.

https://doi.org/10.1182/blood.V124.21.738.738

Published: 2014

Journal Articles

Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia

Markus Pfirrmann, PhD, Susanne Saussele, MD PhD, Michele Baccarani, MD PhD, Joelle Guilhot, PhD, Francisco Cervantes, MD PhD, Gert J Ossenkoppele, MDPhD, Doris Lindoerfer, Verena S Hoffmann, Dr., Fausto Castagnetti, MD PhD, Rüdiger Hehlmann, MD, Bengt Simonsson, MD PhD

Blood (2014) 124 (21): 153.

https://doi.org/10.1182/blood.V124.21.153.153

Published: 2014

Journal Articles

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Verena S Hoffmann, PhD, Doris Lindoerfer, Dipl.-Inf., Markus Pfirrmann, PhD, Susanne Saussele, MD, Andreas Hochhaus, MD, Jutta Engel, PhD, MD, Joelle Guilhot, PhD, Gianantonio Rosti, Jiri Mayer, MD, PhD, Karel Indrak, MD, Fausto Castagnetti, Anna Turkina, Andrey Zaritskey, MD, PhD, Juan Luis Steegmann, MD, PhD, Andrzej Hellmann, Noortje Thielen, MD, Francisco Cervantes, MD, PhD, Bengt Simonsson, MD, PhD, Adriana Colita, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Antonio Almeida, MD, PhD, Boris Labar, MD, PhD, David Marin, MD, Gert J. Ossenkoppele, MD PhD, Andrija Bogdanovic, Irina Dyagil, Kimmo Porkka, MD, PhD, Stephen O'Brien, Laimonas Griskevicius, Panagiotis Panagiotidis, MD, Josef Thaler, MD, Irena Zupan, MD, PhD, Sandra Lejniece, PhD, MD, Hele Everaus, MD, PhD, Tamás Masszi, MD, PhD, Frederiki Melanthiou, Rüdiger Hehlmann, Joerg Hasford, MD, Michele Baccarani, MD

Blood (2013) 122 (21): 2735.

https://doi.org/10.1182/blood.V122.21.2735.2735

Published: 2013

Journal Articles

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, MD, Rüdiger Hehlmann, MD, Carlo Gambacorti-Passerini, MD, Stuart Goldberg, MD, H. Jean Khoury, MD, Michael Mauro, MD, Mauricette Michallet, MD, PhD, Ron Paquette, MD, PhD, Bengt Simonsson, MD, PhD, Aimee Foreman, PhD, Hesham Mohamed, MD, Teresa Zyczynski, Pharm.D., MPH, Ishan Hirji, MPH, Catherine Davis, Pharm.D.

Blood (2013) 122 (21): 4026.

https://doi.org/10.1182/blood.V122.21.4026.4026

Published: 2013

Journal Articles

Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006)

Henrik Hjorth-Hansen, MD, PhD, Johan Richter, MD, PhD, Leif Stenke, MD, PhD, Hans Ehrencrona, MD, PhD, Bjørn Tore Gjertsen, MD, PhD, Tobias Gedde-Dahl, III, MD, PhD, Perttu Koskenvesa, MD, Claes Malm, MD, Waleed Majeed, MD, Lotta Ohm, MD PhD, Martin Hoglund, MD PhD, Ulla Olsson-Strömberg, MD, PhD, Stina Söderlund, MD, Merja Suominen, MD, Kari Remes, MD PhD, Berit Markevärn, MD, Bengt Simonsson, MD PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 4032.

https://doi.org/10.1182/blood.V122.21.4032.4032

Published: 2013

Journal Articles

Overall Survival and Prognosis In Patients With First-Line Imatinib Treatment Under Consideration Of Death Due To Any Cause and Death Due To Chronic Myeloid Leukemia Only

Markus Pfirrmann, PhD, Susanne Saussele, MD, Michele Baccarani, MD, Joelle Guilhot, PhD, Francisco Cervantes, MD, PhD, Gert J. Ossenkoppele, MD PhD, Doris Lindörfer, MSc, Verena S Hoffmann, PhD, Fausto Castagnetti, Rüdiger Hehlmann, MD, Bengt Simonsson, MD, PhD

Blood (2013) 122 (21): 382.

https://doi.org/10.1182/blood.V122.21.382.382

Published: 2013

Journal Articles

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Blood (2013) 122 (7): 1284–1292.

https://doi.org/10.1182/blood-2013-04-495598

Published: 2013

Journal Articles

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Blood (2013) 122 (6): 872–884.

https://doi.org/10.1182/blood-2013-05-501569

Published: 2013

Includes: Supplemental data

Journal Articles

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

Joëlle Guilhot, Michele Baccarani, Richard E. Clark, Francisco Cervantes, François Guilhot, Andreas Hochhaus, Sergei Kulikov, Jiri Mayer, Andreas L. Petzer, Gianantonio Rosti, Philippe Rousselot, Giuseppe Saglio, Susanne Saussele, Bengt Simonsson, Juan-Luis Steegmann, Andrey Zaritskey, Rüdiger Hehlmann

Blood (2012) 119 (25): 5963–5971.

https://doi.org/10.1182/blood-2011-10-383711

Published: 2012

Journal Articles

The EUTOS CML score aims to support clinical decision-making

Verena Hoffmann, Michele Baccarani, Joerg Hasford, Joelle Guilhot, Susanne Saussele, Gianantonio Rosti, François Guilhot, Kimmo Porkka, Gert Ossenkoppele, Doris Lindoerfer, Bengt Simonsson, Markus Pfirrmann, Rüdiger Hehlmann

Blood (2012) 119 (12): 2966–2967.

https://doi.org/10.1182/blood-2012-01-402511

Published: 2012

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry

Blood (2011) 118 (21): 1688.

https://doi.org/10.1182/blood.V118.21.1688.1688

Published: 2011

Journal Articles

Increased Levels of Myeloid-Derived Suppressor Cells (MDSCs) in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on MDSCs in Vitro

Lisa H Christiansson, M.Sc, Stina Söderlund, MD, Emma Svensson, Mats Bengtsson, MD, PhD, Bengt Simonsson, MD, PhD, Ulla Olsson-Strömberg, MD, PhD, Angelica Loskog, PhD

Blood (2011) 118 (21): 2744.

https://doi.org/10.1182/blood.V118.21.2744.2744

Published: 2011

Journal Articles

ABT-737 Sensitizes B Cell Tumors for Killing by CD19-Retargeted T Cells,

Hannah S C Karlsson, Camilla Lindqvist, PhD, Gabriella Paul-Wetterberg, Helena Jernberg Wiklund, PhD, Kenneth Nilsson, MD, PhD, Bengt Simonsson, MD, PhD, Per Frisk, MD, PhD, Angelica Loskog, PhD

Blood (2011) 118 (21): 4032.

https://doi.org/10.1182/blood.V118.21.4032.4032

Published: 2011

NARROW

Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006)

Overall Survival and Prognosis In Patients With First-Line Imatinib Treatment Under Consideration Of Death Due To Any Cause and Death Due To Chronic Myeloid Leukemia Only

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

The EUTOS CML score aims to support clinical decision-making

Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry

Increased Levels of Myeloid-Derived Suppressor Cells (MDSCs) in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on MDSCs in Vitro

ABT-737 Sensitizes B Cell Tumors for Killing by CD19-Retargeted T Cells,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only